New trial hopes to stop lung transplant failure before it starts
NCT ID NCT07410312
First seen Jun 26, 2026 · Last updated Aug 21, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding the anti-inflammatory drug Anakinra to the solution that donor lungs are stored in can prevent primary graft dysfunction — a serious complication after lung transplant that causes low oxygen and lung inflammation. The study will enroll 20 lung transplant recipients and measure outcomes like graft function on day 3, ICU stay, and hospital stay. It is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Anakinra (a drug that blocks inflammation)
- What this could lead to
- If it works, this could reduce the risk of severe lung injury right after transplant, potentially improving recovery and shortening hospital stays.
- What could go wrong
- This is a very early, small trial (20 people) testing a new use for an existing drug. It may not show clear benefit, and results may not apply to all transplant patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years or older. * Planning to undergo transplantation of the lung. * Willing and able to read, understand, and be capable of giving informed consent. * Use of ex vivo lung perfusion (EVLP) prior to lung transplant. Exclusion Criteria: * Previous or current use of IL-1R antagonist drug. * Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating, such as highly sensitized patients who require additional immunosuppression, multiorgan transplant, and re- transplant.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung transplant recipient are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.